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Resumen
Objective. Treatment of benign brain tumors with single dose radiosurgery is common practice, with proven good results. new
radiation techniques extended this treatment to those patientswith large or previously irradiated lesions and patients not eligible
for surgery. In those cases a decrease in irradiation dose or the use of a fractionation regime is needed in order to minimize the
dose in peripheral structures. The limited tolerance of the optic pathway to single doses is a challenge that we have tried to
overcome by hypofractionation with excellent preliminary results.
Materials and Methods. Between 2006 and 2012, 23 patients with benign CNS lesions related to the visual pathway were treated
using CyberKnife. Most (87%) were meningioma and one schwannoma and two pituitary adenomas. Gender distribution was
39% female and 61% male. Average age was 61 years (12-86). There are 83% lesions located in the skull base. Two patients
were embolized ﬁrst and 57% of patients had previously undergone surgery (2 per patient). One patient (GH secreting pituitary
adenoma) was treated with LINAC-Radiosurgery eight years earlier. Prior to treatment 11 patients (47,8%) had varying degrees
of visual deﬁcits. The mean volume was 37 cc (2,9-127). Three sessions on alternate days were used, except for one patient who
received ﬁve sessions contiguous days. The mean marginal dose in patients treated with three fractions was 21 Gy (7 Gy/session),
range: 18-27 Gy. The optical pathway received a mean total dose of 14 Gy (5 Gy/session), range 8-18. Prophylactic steroids during
radiosurgery were prescribed in 65% of patients.
Results. Mean follow-up was of 24 months (12-43). Local control was obtained in 93%, with a reduction in size in 26% of patients
at a mean volume reduction of 19%. There was visual improvement in three patients and one case of visual ﬁeld deterioration. In
relation to other neurological symptoms, two patients showed clinical worsening but only one of them by disease progression.
GH levels decreased in the patient with the secreting adenoma.
Conclusions. The results are very positive for local control and with low visual toxicity in this group of patients with large brain
tumors in which the optical pathway is compromised or at risk, where the age and the existence of concurrent risk conditions for
surgery is relatively high. Both high volumetric control as the low toxicity and simplicity of the technique makes the CyberKnife
Radiosurgery an excellent and well tolerated alternative for them.
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Resumen
Introduction. Surgery or radiosurgery (RC) followed by whole brain irradiation (WBI) is the treatment of choice in patients (pats)
with brain metastases (BM). The omission of WBI increases cerebral recurrence rate without detriment in overall survival. The
introduction of new systemic therapies have improved survival in metastatic pats raising concerns about long-term toxicities of
WBI. We retrospectively analyzed pats with BM treated with exclusive RC at our institution.
Material and Methods. Inclusion criteria: patients who refused surgery or WBI, life expectancy>1 year, 70%.≥4 MC, primary tumor
and/or oligometastatic disease controlled, Karnofsky ≤ The treatment was performed in an adapted linear accelerator using
circulate collimators or micro-multileafs.
Results. Between 1998 and 2012, 46 pats (32-NSCLC, 6-breast, 4-renal-melanoma and 4-others) with a median age of 57 years and
a total number of 69 BM were treated with RC alone (median dose 16 Gy, 14-19 Gy). Sixty-percent of patients had extracranial
metastatic disease at the time of RC. The median number of BM treated was 1 (1-4), synchronous or metachronous diagnosis were
observed in 34% and 66% of patients, respectively. Twenty-six patients (60%) presented cerebral progression and 23/26 patients
(88%) were rescued with WBI (11pats), RC (3pats), surgery (1pats), chemotherapy (4pats) and combination of these treatments
(4patients). With a median follow up of 62-months, the median survival and the 1,3,.5-y OS were 20 months and 62%, 42% and
32%, respectively. Six of 31 patients (19%) died due to cerebral progression. The 1,3,5-y local-brain-control was 80%, 73% and
73%.The 1,3,5-y overall cerebral recurrence were 47%, 35% and 20%. The 5-y patients free of WBI was 70%.
